NuCana (NCNA)

• Market cap: $4.75M
• 1 day: 0.00%
• 5 days: -6.92%
• 1 month: -5.47%
• 3 months: -62.31%
• 6 months: -58.56%
• Year to date: -84.72%
• 1 year: -83.26%
• 5 years: -99.21%
• 10 years: -99.70%

About: NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.

Employees: 28

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

13% more funds holding

Funds holding: 15 [Q2] → 17 (+2) [Q3]

0.21% less ownership

Funds ownership: 0.66% [Q2] → 0.46% (-0.21%) [Q3]

32% less capital invested

Capital invested by funds: $871K [Q2] → $590K (-$281K) [Q3]